OncoMatch/Clinical Trials/NCT06705075
Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE
Is NCT06705075 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Perfluten for uterine fibroid.
Treatment: Perfluten — This study goals are to determine the patterns of uterine fibroid vascularity pre and post UAE using CEUS resulting in an alternative to gadolinium-enhanced MRI that is less expensive, has less contra-indications and side effects, is real time, and noninvasive helping physicians to evaluate the result of UAE procedures. Also, this study will evaluate uterine fibroid pressures using SHAPE, comparing the results with normal myometrium tissue in order to determine its characteristics and tissue differences, which we believe will lead to the development of a new biomarker for the diagnosis and treatment of uterine fibroids.
Check if I qualifyExtracted eligibility criteria
Prior therapy
Cannot have received: investigational drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Thomas Jefferson University · Philadelphia, Pennsylvania
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify